Browse by Audience
Skip to content
Papers of the Week
Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B.
Abstract
In patients with chronic hepatitis B (CHB) infection, activation of toll-like receptor 8 (TLR8) may induce antiviral immunity and drive functional cure. Selgantolimod, a novel TLR8 agonist, was evaluated in CHB patients who were virally suppressed on oral antiviral treatment (OAV) or viremic not on OAV.